• Health & Medicine

Cancer Research Technology, The ICR and ZoBio BV sign deal to develop cancer drugs

Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) have signed a deal with Dutch drug discovery company, ZoBio BV, to discover and develop drugs to block a DNA repair target which may play a role in cancer cell survival. Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) have signed a deal with Dutch drug discovery company, ZoBio BV, to discover and develop drugs to block a DNA repair target which may play a role in cancer cell survival.

10 March 2011

Cancer Research UK and Cancer Research Technology establish team of stem cell experts to beat cancer

Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer. Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer.

14 January 2011

Cancer Research UK and AstraZeneca collaborate to trial combinations of new cancer drugs

Cancer Research UK's drug development office (DDO) has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials. Cancer Research UK's drug development office (DDO) has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.

13 January 2011

• Science & Technology

CRT and Bayer Schering Pharma to investigate new therapeutic approach in gynaecological and oncological diseases

CANCER RESEARCH TECHNOLOGY has signed an agreement with Bayer Schering Pharma AG, Germany to evaluate new leptin antagonist peptides as potential experimental treatments initially in the area of gynaecological diseases, including cancer. CANCER RESEARCH TECHNOLOGY has signed an agreement with Bayer Schering Pharma AG, Germany to evaluate new leptin antagonist peptides as potential experimental treatments initially in the area of gynaecological diseases, including cancer.

25 August 2010

• Science & Technology
• Health & Medicine

CRT and ValiRx sign licensing deal to develop prostate cancer treatment

CANCER RESEARCH TECHNOLOGY has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. CANCER RESEARCH TECHNOLOGY has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.

12 August 2010

• Science & Technology
• Health & Medicine

'Skills Swap' to exploit expertise for patient benefit

Cancer Research Technology (CRT) and Medical Research Council Technology (MRCT) will 'swap' medical discoveries to accelerate the translation of early scientific research into patient benefit. Cancer Research Technology (CRT) and Medical Research Council Technology (MRCT) will 'swap' medical discoveries to accelerate the translation of early scientific research into patient benefit.

13 July 2010

• Science & Technology
• Health & Medicine

UK-NZ collaboration to home in on new anti-cancer drug for leukaemia

Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia. Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

22 April 2010

• Science & Technology

CRT announces partnership with Cephalon to co-develop a new class of anti-cancer drugs

Cancer Research Technology (CRT) has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the Protein Kinase C superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer. Cancer Research Technology (CRT) has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the Protein Kinase C superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 March 2010

• Health & Medicine

Cancer Research UK and immatics Biotechnologies to trial vaccine for brain cancer

Cancer Research UK and Cancer Research Technology have reached a collaboration agreement with immatics Biotechnologies to trial their new vaccine. Cancer Research UK and Cancer Research Technology have reached a collaboration agreement with immatics Biotechnologies to trial their new vaccine.

16 February 2010

• Health & Medicine
• Science & Technology

CRT and AstraZeneca form major alliance to create cancer metabolism drugs

Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday). Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

7 February 2010

Scientists scoop top prize for light-based detection technology

CyMap, an innovative lens-free microscope developed by Cancer Research UK scientists and members of the Optical Biochips Consortium*, has won first prize in the Medical and Healthcare category of The Engineer's Technology and Innovation Awards as well as the overall Grand Prix prize. CyMap, an innovative lens-free microscope developed by Cancer Research UK scientists and members of the Optical Biochips Consortium*, has won first prize in the Medical and Healthcare category of The Engineer's Technology and Innovation Awards as well as the overall Grand Prix prize.

11 December 2009

• Health & Medicine

CRT to licence telomere targeting agents to Pharminox for drug development

Cancer Research Technology (CRT) - Cancer Research UK's development and commercial arm - and the cancer drug discovery company Pharminox Ltd (Pharminox) today announced that CRT has granted Pharminox an exclusive worldwide licence over its programme targeting telomeres and telomerase - the enzyme that is responsible for maintaining them. Cancer Research Technology (CRT) - Cancer Research UK's development and commercial arm - and the cancer drug discovery company Pharminox Ltd (Pharminox) today announced that CRT has granted Pharminox an exclusive worldwide licence over its programme targeting telomeres and telomerase - the enzyme that is responsible for maintaining them.

13 October 2009